search
Back to results

Evaluation of the Dermal Cooling System for the Enhanced Treatment of Benign Pigmented Lesions and Common Skin Conditions

Primary Purpose

Pigmentation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dermal Cooling System
Sponsored by
R2 Dermatology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pigmentation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male or female subjects > 18 years of age.
  2. Subject has one or more benign pigmented lesions (e.g., solar lentigines, freckles, seborrheic keratosis), in an area suitable for treatment.
  3. Subject is willing to have up to 40 treatment sites treated per treatment session depending on the size and nature of the lesions identified.
  4. Subject is willing to have digital photographs taken of the treatment area and agrees to use of photographs for presentation, educational, or marketing purposes.
  5. Subject is willing to cover treated area or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area for the duration of the study, including the follow-up period, if requested.
  6. Subject has read and signed a written informed consent form.
  7. Subject is willing to comply with adjuvant topical regimen, as applicable. -

Exclusion Criteria:

  1. Physician prescribed medical or surgical treatment, or use of over-the-counter products to alter skin color, in the area of intended treatment in the previous 6 months (e.g., hydroquinone, corticosteroids, laser surgery)
  2. Use of products containing glycolic acids, retinol, salicylic acid within the previous 2 weeks
  3. Use of Accutane within the previous 6 months
  4. Artificial tanning in the area of intended treatment within 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period
  5. Scars or tattoos in the location of the treatment sites
  6. History of melasma, vitiligo, eczema, or psoriasis in the area of treatment
  7. History of melanoma
  8. Subject is pregnant or intending to become pregnant during the study period
  9. Subject is lactating or has been lactating in the past 6 months
  10. Known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia, cold urticaria, paroxysmal cold hemoglobinuria, Reynaud's disease.
  11. History of abnormal wound healing or abnormal scarring
  12. Inability or unwillingness to comply with the study requirements.
  13. Current enrollment in a clinical study of any other unapproved investigational drug or device.
  14. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.

    -

Sites / Locations

  • Sculptology

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment with Dermal Cooling System

Arm Description

Dermal Cooling System will be used in all eligible subjects.

Outcomes

Primary Outcome Measures

Improvement in the appearance of the treated areas as assessed by Investigator assessment.
Investigator assessment using Global Aesthetic Improvement Scale (GAIS); graded from "4" (very much improved") to "0" (worse).
Safety of the treatment
Determined by incidence of device-or procedure-related adverse events

Secondary Outcome Measures

Full Information

First Posted
July 26, 2020
Last Updated
August 28, 2023
Sponsor
R2 Dermatology
search

1. Study Identification

Unique Protocol Identification Number
NCT04493021
Brief Title
Evaluation of the Dermal Cooling System for the Enhanced Treatment of Benign Pigmented Lesions and Common Skin Conditions
Official Title
Evaluation of the Dermal Cooling System for the Enhanced Treatment of Benign Pigmented Lesions and Common Skin Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
July 7, 2020 (Actual)
Primary Completion Date
May 31, 2022 (Actual)
Study Completion Date
May 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
R2 Dermatology

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the Dermal Cooling System for lightening of benign pigmented lesions and to assess additional cosmetic benefits.
Detailed Description
This is a prospective, non-randomized, open-label study to evaluate the effectiveness of the Dermal Cooling system to reduce pigmentation in benign pigmented lesions and to determine if additional cosmetic benefits are achieved.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pigmentation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
137 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment with Dermal Cooling System
Arm Type
Experimental
Arm Description
Dermal Cooling System will be used in all eligible subjects.
Intervention Type
Device
Intervention Name(s)
Dermal Cooling System
Intervention Description
Controlled localized cooling will be applied to benign pigmented lesions using the Dermal Cooling System
Primary Outcome Measure Information:
Title
Improvement in the appearance of the treated areas as assessed by Investigator assessment.
Description
Investigator assessment using Global Aesthetic Improvement Scale (GAIS); graded from "4" (very much improved") to "0" (worse).
Time Frame
2-Month Follow-up visit
Title
Safety of the treatment
Description
Determined by incidence of device-or procedure-related adverse events
Time Frame
Up to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female subjects > 18 years of age. Subject has one or more benign pigmented lesions (e.g., solar lentigines, freckles, seborrheic keratosis), in an area suitable for treatment. Subject is willing to have up to 40 treatment sites treated per treatment session depending on the size and nature of the lesions identified. Subject is willing to have digital photographs taken of the treatment area and agrees to use of photographs for presentation, educational, or marketing purposes. Subject is willing to cover treated area or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area for the duration of the study, including the follow-up period, if requested. Subject has read and signed a written informed consent form. Subject is willing to comply with adjuvant topical regimen, as applicable. - Exclusion Criteria: Physician prescribed medical or surgical treatment, or use of over-the-counter products to alter skin color, in the area of intended treatment in the previous 6 months (e.g., hydroquinone, corticosteroids, laser surgery) Use of products containing glycolic acids, retinol, salicylic acid within the previous 2 weeks Use of Accutane within the previous 6 months Artificial tanning in the area of intended treatment within 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period Scars or tattoos in the location of the treatment sites History of melasma, vitiligo, eczema, or psoriasis in the area of treatment History of melanoma Subject is pregnant or intending to become pregnant during the study period Subject is lactating or has been lactating in the past 6 months Known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia, cold urticaria, paroxysmal cold hemoglobinuria, Reynaud's disease. History of abnormal wound healing or abnormal scarring Inability or unwillingness to comply with the study requirements. Current enrollment in a clinical study of any other unapproved investigational drug or device. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject. -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andre Bonnett, MD
Organizational Affiliation
Sculptology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sculptology
City
Pleasanton
State/Province
California
ZIP/Postal Code
94566
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Evaluation of the Dermal Cooling System for the Enhanced Treatment of Benign Pigmented Lesions and Common Skin Conditions

We'll reach out to this number within 24 hrs